-
The basic demographic characteristics of subjects included age, sex, height, and weight. In the discovery study, all of the data in three groups conformed to a normal distribution, and no statistical differences existed among groups. In the validation study,
the basic characteristics in three groups were not normally distributed (P < 0.05) because there were fewer subjects in the internal control and case groups. The basic characteristics of children were shown in Table 1. Cohort Indexes External control group Internal control group Case group Discovery cohort* Total number 50 51 56 Sex (male/female) 28/22 30/21 25/31 Age (years) 12.5 ± 1.09 12.09 ± 1.21 12.24 ± 1.55 Height (cm) 142.68 ± 6.84 141.63 ± 6.19 142.89 ± 6.26 Weight (kg) 34.36 ± 5.22 33.84 ± 4.83 34.50 ± 4.96 Validation cohort# Total number 50 41 31 Sex (male/female) 25/25 24/17 14/17 Age (years) 10.0 (8.0, 10.0) 11.0 (10.0, 12.0) 12.0 (10.0, 13.0) Height (cm) 129.5 (122.2, 135.0) 136.0 (129.0, 140.0) 137.0 (132.5, 154.5) Weight (kg) 26.0 (23.0, 29.0) 30.5 (26.0, 35.0) 32.0 (25.5, 39.5) Note. *The age, height and weight of the subjects in the three groups all followed the normal distribution and had the same variance, with no statistical difference (P > 0.05). #The age, height and weight of the three groups were not subject to normal distribution, with statistically significant differences (P < 0.05). Table 1. The demographic characteristics of subjects in two-stage study
-
The detection stage in serum identified 7,064 metabolites and 1,879 metabolites with VIP > 1. Using non-parametric tests, 1,384 metabolites with statistical significance among three groups (P < 0.05) were selected. By searching online databases (Metlin and HMDB), eight endogenous metabolites potentially closely associated with KBD were discovered, namely, kynurenic acid, N-α-acetylarginine, 6-hydroxymelatonin, sphinganine, ceramide, sphingosine-1P, spermidine, and glycine. The details of metabolites can be seen in Table 2.
Metabolites m/z (Da) RT (min) VIP Variation trends P value Kynurenic acid 190.084 4.526 2.492 + < 0.0001 N-α-acetylarginine 217.098 1.626 1.573 − 0.0040 6-hydroxymelatonin 249.158 14.695 1.578 − < 0.0001 Sphinganine 302.306 1.056 2.596 − < 0.0001 Ceramide 330.332 16.913 1.935 + < 0.0001 Glycine 362.241 8.784 2.835 − < 0.0001 Sphingosine 1-phosphate 394.232 19.232 2.318 − < 0.0001 Spermidine 674.258 10.697 1.907 + 0.0010 Note. +: The metabolite level of the case group was higher than that of the control groups; -: The metabolite level of the case group was lower than that of the external control group. Table 2. Endogenous difference metabolites in serum associated with KBD selected in discovery study
-
Except for ceramide, seven substances selected in the discovery study were determined by HPLC-Q-TRAP-MS. Five candidate metabolites were validated and they were kynurenic acid, N-α-acetylarginine, sphinganine, spermidine, and sphingosine-1P. The levels of these substances and statistical analysis results are shown in Table 3. With the exception of spermidine, the other four substances showed low expression in the case group. Between the two control groups, with the exception of sphinganine the levels of the other four substances showed higher expression in the internal control group. The details are presented in Figure 2.
Metabolites External control group Internal control group Case group P value Kynurenic acid* 1.60 (0.97, 2.18)a 2.82 (1.90, 4.32)b 1.15 (0.68, 1.81)a < 0.0001 N-α-Acetylarginine 28.41 ± 17.12a 47.36 ± 19.57b 19.98 ± 9.17a < 0.0001 Sphinganine 8.22 ± 2.43a 6.94 ± 2.37ab 6.20 ± 2.05b 0.0240 Spermidine* 19.20 (14.78, 29.38)a 43.70 (35.38, 67.48)b 30.10 (21.00, 50.53)b < 0.0001 Sphingosine 1P 709.25 ± 149.73a 799.30 ± 139.61a 591.75 ± 115.31b < 0.0001 Note. *The data did not conform to the normal distribution and was described by the median (quartile); other data conformed to normal distribution, expressed as mean ± standard deviation. a and b represented statistically significant among case group, external control group and internal control group, respectively, different letter means difference and one same letter means no-difference. Table 3. Verified difference metabolites and the level among three groups in validation cohort (ng/mL)
-
An ROC curve was constructed in order to evaluate the potential of single metabolites validated in the second cohort for disease recognition. The results were as follows: between the internal control group and case group, the AUC of kynurenic acid, N-α-acetylarginine, sphinganine, spermidine, and sphingosine-1P was 0.85, 0.88, 0.58, 0.66, and 0.87, respectively; between the external control group and case group, the AUC of five metabolites was 0.63, 0.64, 0.74, 0.74, and 0.75, respectively; between the two control groups, the AUC of five metabolites was 0.78, 0.75, 0.67, 0.87, and 0.67, respectively. Details are shown in Figure 3.
-
In this study, the metabolic pathways in which the eight metabolites found in the discovery study were identified and analyzed. Results showed that these metabolites were mainly involved in three metabolic pathways, namely sphingolipid metabolism, glutathione metabolism and tryptophan metabolism, in which, the impact value of sphingolipid metabolism was maximal (up to 0.46; Table 4). The sphingolipid metabolism pathway included sphinganine, ceramide, and sphingosine-1P; the glutathione metabolism pathway included spermidine and glycine; and kynurenic acid and 6-hydroxymelatonin were included in the tryptophan metabolism pathway.
Pathways Total Hits Raw P -Log (P) Holm adjust P FDR PI Sphingolipid metabolism 25 3 0.0010 6.9000 0.08 0.08 0.4602 Glutathione metabolism 38 2 0.0386 3.2600 1.00 0.91 0.0361 Tryptophan metabolism 79 3 0.0259 3.6500 1.00 0.91 0.0114 Note. Total means the total number of compounds in the pathway; Hits means the number of actual matches between the input metabolites and the compounds in the pathway; Raw P is the original P value derived from the enrichment analysis and < 0.05 means significance; PI means the impact factor of the pathway, which is obtained through topological analysis and it is significant when PI > 0.01. Table 4. The results of metabolic pathways analysis
Serum Metabolomic Indicates Potential Biomarkers and Metabolic Pathways of Pediatric Kashin-Beck Disease
doi: 10.3967/bes2020.100
- Received Date: 2019-10-02
- Accepted Date: 2020-01-13
-
Key words:
- Kashin-Beck disease /
- Potential biomarkers /
- Metabolism pathways /
- Serum
Abstract:
Citation: | WANG Yu Meng, WANG Wei Yi, SUN Li Yan, LI Qiang, ZHAO Zhi Jun, HU Jian, ZHANG Rong Yu, WANG Li Hua. Serum Metabolomic Indicates Potential Biomarkers and Metabolic Pathways of Pediatric Kashin-Beck Disease[J]. Biomedical and Environmental Sciences, 2020, 33(10): 750-759. doi: 10.3967/bes2020.100 |